Literature DB >> 9466769

Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin. The Grupo Andaluz para el estudio de las Enfermedades Infecciosas.

F J Caballero-Granado1, J M Cisneros, R Luque, M Torres-Tortosa, F Gamboa, F Díez, J L Villanueva, R Pérez-Cano, J Pasquau, D Merino, A Menchero, D Mora, M A López-Ruz, A Vergara.   

Abstract

A prospective, multicenter study was carried out over a period of 10 months. All patients with clinically significant bacteremia caused by Enterococcus spp. were included. The epidemiological, microbiological, clinical, and prognostic features and the relationship of these features to the presence of high-level resistance to gentamicin (HLRG) were studied. Ninety-three patients with enterococcal bacteremia were included, and 31 of these cases were caused by HLRG (33%). The multivariate analysis selected chronic renal failure, intensive care unit stay, previous use of antimicrobial agents, and Enterococcus faecalis species as the independent risk factors that influenced the development of HLRG. The strains with HLRG showed lower levels of susceptibility to penicillin and ciprofloxacin. Clinical features (except for chronic renal failure) were similar in both groups of patients. HLRG did not influence the prognosis for patients with enterococcal bacteremia in terms of either the crude mortality rate (29% for patients with bacteremia caused by enterococci with HLRG and 28% for patients not infected with strains with HLRG) or the hospital stay after the acquisition of enterococcal bacteremia. Hemodynamic compromise, inappropriate antimicrobial therapy, and mechanical ventilation were revealed in the multivariate analysis to be the independent risk factors for mortality. Prolonged hospitalization was associated with the nosocomial acquisition of bacteremia and polymicrobial infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466769      PMCID: PMC104570     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Two distinct forms of vancomycin resistance amongst enterococci in the UK.

Authors:  N Woodford; A P Johnson; D Morrison; A T Chin; J R Stephenson; R C George
Journal:  Lancet       Date:  1990-01-27       Impact factor: 79.321

Review 2.  [Enterococcal endocarditis, a model of therapeutic difficulty].

Authors:  M L Fernández Guerrero; A Núñez García
Journal:  Rev Clin Esp       Date:  1995-10       Impact factor: 1.556

Review 3.  High-level gentamicin resistance in Enterococcus: microbiology, genetic basis, and epidemiology.

Authors:  J E Patterson; M J Zervos
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

Review 4.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

5.  A three-year study of positive blood cultures, with emphasis on prognosis.

Authors:  F J Roberts; I W Geere; A Coldman
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

6.  High-level vancomycin-resistant enterococci causing hospital infections.

Authors:  A H Uttley; R C George; J Naidoo; N Woodford; A P Johnson; C H Collins; D Morrison; A J Gilfillan; L E Fitch; J Heptonstall
Journal:  Epidemiol Infect       Date:  1989-08       Impact factor: 2.451

7.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

8.  Enterococcal bacteremia in two large community teaching hospitals.

Authors:  D A Malone; R A Wagner; J P Myers; C Watanakunakorn
Journal:  Am J Med       Date:  1986-10       Impact factor: 4.965

Review 9.  Enterococcal bacteremia: clinical features, the risk of endocarditis, and management.

Authors:  D G Maki; W A Agger
Journal:  Medicine (Baltimore)       Date:  1988-07       Impact factor: 1.889

10.  [Enterococci: high level of resistance to aminoglycosides].

Authors:  O del Valle-Ortiz; C Gallés; G Codina; A Cano
Journal:  Enferm Infecc Microbiol Clin       Date:  1989-12       Impact factor: 1.731

View more
  13 in total

Review 1.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 2.  Pathogenicity of Enterococci.

Authors:  Elizabeth Fiore; Daria Van Tyne; Michael S Gilmore
Journal:  Microbiol Spectr       Date:  2019-07

3.  Intravenous mouse infection model for studying the pathology of Enterococcus faecalis infections.

Authors:  Claudia Gentry-Weeks; Monica Estay; Cindy Loui; Dale Baker
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

Review 4.  [Diagnosis and therapy of sepsis].

Authors:  K Reinhart; F M Brunkhorst; H-G Bone; H Gerlach; M Gründling; G Kreymann; P Kujath; G Marggraf; K Mayer; A Meier-Hellmann; C Peckelsen; C Putensen; F Stüber; M Quintel; M Ragaller; R Rossaint; N Weiler; T Welte; K Werdan
Journal:  Clin Res Cardiol       Date:  2006-08       Impact factor: 5.460

5.  [Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI)].

Authors:  K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte
Journal:  Anaesthesist       Date:  2010-04       Impact factor: 1.041

Review 6.  A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

Review 7.  [Diagnosis and therapy of sepsis. Guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine].

Authors:  K Reinhart; F Brunkhorst; H Bone; H Gerlach; M Gründling; G Kreymann; P Kujath; G Marggraf; K Mayer; A Meier-Hellmann; C Peckelsen; C Putensen; M Quintel; M Ragaller; R Rossaint; F Stüber; N Weiler; T Welte; K Werdan
Journal:  Internist (Berl)       Date:  2006-04       Impact factor: 0.743

8.  Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)).

Authors:  K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte
Journal:  Ger Med Sci       Date:  2010-06-28

9.  Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia--a five-year retrospective review.

Authors:  S J McBride; A Upton; S A Roberts
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-15       Impact factor: 3.267

10.  Clinical features, risk factors and outcomes of bacteremia due to enterococci with high-level gentamicin resistance: comparison with bacteremia due to enterococci without high-level gentamicin resistance.

Authors:  Hee-Chang Jang; Shinwon Lee; Kyoung-Ho Song; Jae Hyun Jeon; Wan Beom Park; Sang-Won Park; Hong Bin Kim; Nam Joong Kim; Eui-Chong Kim; Myoung-Don Oh; Kang Won Choe
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.